OxiLast Achieves Long-Lasting Reduction of Healthcare-Associated Pathogens in Hospital Rooms

The Hadassah Medical Center conducted a study to test the effectiveness of OxiLast in killing MRSA and Klebsiella pneumoniae (Kp) on surfaces in patient rooms.

The surfaces were treated with OxiLast once on day 0 (D₀), and then were contaminated with 10⁶ of resistant bacteria, on consecutive days till day 7 (D₇).

Reduction in live bacterial counts were determined by quantitative cultures.
The study compared the effectiveness of OxiLast to the current hospital sanitation protocol.

“I was impressed by the product’s strong and long lasting efficacy. I’m eager to see how it performs in a clinical hospital setting”
Yonatan Oster, MD
Head of the unit for Infection Prevention and Control
Hadassah Medical Center

Surfaces treated with OxiLast demonstrated a notable decrease in viable bacterial counts, maintaining this effect for up to seven days

The average reduction was 5.4 log for Klebsiella pneumonia (Kp) and 4.9 log for MRSA.

 Comparable outcomes were noted with clinical isolates of both MRSA and Kp.

Additionally, the efficacy of OxiLast persisted even after introducing organic materials, which mimic contamination from bodily fluids in patient areas.

In contrast, the control group using only chlorine exhibited no lasting effects, with a minimal reduction of less than 1 log noted

“I was impressed by the product’s strong and long lasting efficacy. I’m eager to see how it performs in a clinical hospital setting”